Mechanistically, SET over-expression and the resulting PP2A inhibition is critical for the maintenance of the leukemogenic program by BCR::ABL in CML [21, 27]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.